Urethra cancer
diseaseOn this page
Also known as cancer of urethramalignant neoplasm of the urethramalignant neoplasm of urethramalignant tumor of the urethramalignant tumor of urethramalignant tumour of the urethramalignant urethra neoplasmmalignant urethra tumormalignant urethra tumourmalignant urethral neoplasmmalignant urethral tumormalignant urethral tumoururethral cancer
Summary
Urethra cancer (MONDO:0004192) is a cancer (an umbrella term covering 5 Mondo subtypes) and 73 clinical trials. Top therapeutic interventions include cisplatin, cabozantinib, and vinblastine. A subtype of malignant urinary system neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 5 Mondo subtypes
- Clinical trials: 73
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | urethra cancer |
| Mondo ID | MONDO:0004192 |
| DOID | DOID:734 |
| ICD-10-CM | C68.0 |
| ICD-11 | 1707814375 |
| NCIT | C7507 |
| SNOMED CT | 363459007 |
| UMLS | C0153620 |
| MedGen | 57565 |
| GARD | 0009390 |
| Anatomy (UBERON) | UBERON:0000057 |
| Is cancer (heuristic) | yes |
Also known as: cancer of urethra · malignant neoplasm of the urethra · malignant neoplasm of urethra · malignant tumor of the urethra · malignant tumor of urethra · malignant tumour of the urethra · malignant urethra neoplasm · malignant urethra tumor · malignant urethra tumour · malignant urethral neoplasm · malignant urethral tumor · malignant urethral tumour · urethra cancer · urethral cancer
Disease family
This is a subtype of malignant urinary system neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant urinary system neoplasm › urethra cancer
Related subtypes (9): malignant prostate phyllodes tumor, urinary bladder cancer, kidney cancer, multiple endocrine neoplasia type 2B, ureter cancer, pheochromocytoma/paraganglioma syndrome 2, pheochromocytoma/paraganglioma syndrome 5, infiltrating urothelial carcinoma, urothelial carcinoma
Subtypes (5): male urethral cancer, female urethral cancer, posterior urethra cancer, anterior urethra cancer, carcinoma of urethra
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 73.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 44 |
| PHASE1 | 11 |
| Not specified | 7 |
| PHASE3 | 6 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05092958 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study |
| NCT00003376 | PHASE3 | COMPLETED | Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium |
| NCT00003701 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Patients With Bladder Cancer |
| NCT00014274 | PHASE2/PHASE3 | COMPLETED | Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium |
| NCT00022191 | PHASE3 | COMPLETED | Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer |
| NCT00942331 | PHASE3 | COMPLETED | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer |
| NCT03296306 | PHASE3 | UNKNOWN | Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma |
| NCT00082706 | PHASE2 | ACTIVE_NOT_RECRUITING | Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant |
| NCT03237780 | PHASE2 | ACTIVE_NOT_RECRUITING | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer |
| NCT03866382 | PHASE2 | RECRUITING | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
| NCT04848519 | PHASE2 | ACTIVE_NOT_RECRUITING | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma |
| NCT04940299 | PHASE2 | ACTIVE_NOT_RECRUITING | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma |
| NCT04953104 | PHASE2 | ACTIVE_NOT_RECRUITING | ARID1A and/or KDM6A Mutation and CXCL13 Expression |
| NCT05756569 | PHASE2 | RECRUITING | Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology |
| NCT05888532 | PHASE1/PHASE2 | RECRUITING | 64Cu-GRIP B in Patients With Advanced Malignancies |
| NCT00002684 | PHASE2 | COMPLETED | Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer |
| NCT00002914 | PHASE2 | COMPLETED | Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract |
| NCT00003175 | PHASE2 | COMPLETED | Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer |
| NCT00004223 | PHASE2 | COMPLETED | Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer |
| NCT00004856 | PHASE2 | TERMINATED | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium |
| NCT00005644 | PHASE2 | COMPLETED | Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function |
| NCT00006026 | PHASE2 | COMPLETED | Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract |
| NCT00006111 | PHASE2 | COMPLETED | Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract |
| NCT00006351 | PHASE2 | COMPLETED | SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract |
| NCT00009867 | PHASE2 | COMPLETED | Arsenic Trioxide in Treating Patients With Urothelial Cancer |
| NCT00014144 | PHASE2 | COMPLETED | S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract |
| NCT00021099 | PHASE2 | COMPLETED | Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer |
| NCT00022633 | PHASE2 | TERMINATED | S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract |
| NCT00045630 | PHASE2 | COMPLETED | S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium |
| NCT00053209 | PHASE2 | COMPLETED | Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium |
| NCT00055835 | PHASE2 | COMPLETED | S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium |
| NCT00066612 | PHASE2 | COMPLETED | S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy |
| NCT00072150 | PHASE2 | COMPLETED | Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma |
| NCT00080795 | PHASE2 | COMPLETED | Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium |
| NCT00087295 | PHASE2 | TERMINATED | S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium |
| NCT00112905 | PHASE2 | TERMINATED | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium |
| NCT00397488 | PHASE2 | COMPLETED | Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium |
| NCT00407485 | PHASE2 | COMPLETED | VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium |
| NCT00471536 | PHASE2 | COMPLETED | Pazopanib in Treating Patients With Metastatic Urothelial Cancer |
| NCT00478361 | PHASE2 | COMPLETED | Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 16 |
| CABOZANTINIB | 4 | 7 |
| VINBLASTINE | 4 | 4 |
| CARBOPLATIN | 4 | 3 |
| GEMCITABINE | 4 | 3 |
| PACLITAXEL | 4 | 3 |
| SUNITINIB MALATE | 4 | 3 |
| DOXORUBICIN HYDROCHLORIDE | 4 | 2 |
| PAZOPANIB HYDROCHLORIDE | 4 | 2 |
| ARSENIC TRIOXIDE | 4 | 1 |
| AVELUMAB | 4 | 1 |
| FLUDEOXYGLUCOSE F 18 | 4 | 1 |
| GEFITINIB | 4 | 1 |
| IXABEPILONE | 4 | 1 |
| LONAFARNIB | 4 | 1 |
| ROMIDEPSIN | 4 | 1 |
| SORAFENIB | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| RUBITECAN | 3 | 1 |
| AZD-4877 | 2 | 1 |
| PIRITREXIM | 2 | 1 |
| CHEMBL48 | 0 | 3 |
| CHEMBL3109278 | 0 | 3 |
| CHEMBL4788494 | 0 | 2 |
| CHEMBL376464 | 0 | 2 |